Journal of Clinical Oncology, Vol 22, No 18 (September 15), 2004: pp. 3805-3812
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.01.083
Systematic Review of the Staging Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer
H.L. van Westreenen,
M. Westerterp,
P.M.M. Bossuyt,
J. Pruim,
G.W. Sloof,
J.J.B. van Lanschot,
H. Groen,
J.Th.M. Plukker
From the Department of Surgery, Department of Nuclear Medicine/PET Center, and Office for Medical Technology Assessment, University Hospital Groningen, Groningen, the Netherlands; Department of Surgery, Department of Clinical Epidemiology and Biostatistics, and Department of Nuclear Medicine, Academic Medical Center, Amsterdam, the Netherlands
Address reprint requests to J.Th.M. Plukker, MD, PhD, Department of Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands; e-mail: j.th.plukker{at}chir.azg.nl
PURPOSE: Despite the increasing number of publications concerning 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for staging of esophageal cancer and the increasing availability of this novel diagnostic modality, its exact role in preoperative staging of these tumors is still unknown. The aim of this study was to systematically review the literature regarding the diagnostic performance of FDG-PET in preoperative staging of patients with esophageal cancer, and to calculate summary estimates of its sensitivity and specificity.
METHODS: The databases of PubMed, Embase, and Cochrane were searched for relevant studies. Two reviewers independently assessed the methodological quality of each study. A meta-analysis of the reported sensitivity and specificity of each study was performed.
RESULTS: Twelve studies met the inclusion criteria. The studies had several design deficiencies. Pooled sensitivity and specificity for the detection of locoregional metastases were 0.51 (95% CI, 0.34 to 0.69) and 0.84 (95% CI, 0.76 to 0.91), respectively. For distant metastases, pooled sensitivity and specificity were 0.67 (95% CI, 0.58 to 0.76) and 0.97 (95% CI, 0.90 to 1.0), respectively.
CONCLUSION: FDG-PET showed moderate sensitivity and specificity for the detection of locoregional metastases, and reasonable sensitivity and specificity in detection of distant lymphatic and hematogenous metastases.
This study was supported by ZonMw Program for Health Care Efficiency Research.
Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. A. Podoloff, D. W. Ball, E. Ben-Josef, A. B. Benson III, S. J. Cohen, R. E. Coleman, D. Delbeke, M. Ho, D. H. Ilson, G. P. Kalemkerian, et al.
NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
J Natl Compr Canc Netw,
June 1, 2009;
7(Suppl_2):
S-1 - S-23.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-H. Hsu, P.-K. Hsu, S.-J. Wang, K.-H. Lin, C.-S. Huang, C.-C. Hsieh, and Y.-C. Wu
Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma.
Ann. Thorac. Surg.,
May 1, 2009;
87(5):
1564 - 1568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kim, H. Y. Kim, K. W. Lee, and M. S. Kim
Multimodality Assessment of Esophageal Cancer: Preoperative Staging and Monitoring of Response to Therapy1
RadioGraphics,
March 1, 2009;
29(2):
403 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G A WHITFIELD, A JACKSON, C MOORE, and P PRICE
Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: what planning margins should we use?
Br. J. Radiol.,
December 1, 2008;
81(972):
921 - 934.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-Y. Chang, J.-Y. Chang, J. Chao, and Y. Yen
Modern Staging and Utility of PET Imaging in Esophageal Cancer Management
J Natl Compr Canc Netw,
October 1, 2008;
6(9):
862 - 869.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hazard, G. Yang, M. F. McAleer, J. Hayman, and C. Willett
Principles and Techniques of Radiation Therapy for Esophageal and Gastroesophageal Junction Cancers
J Natl Compr Canc Netw,
October 1, 2008;
6(9):
870 - 878.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Berrisford, W.-L. Wong, D. Day, E. Toy, M. Napier, K. Mitchell, and S. Wajed
The decision to operate: role of integrated computed tomography positron emission tomography in staging oesophageal and oesophagogastric junction cancer by the multidisciplinary team
Eur. J. Cardiothorac. Surg.,
June 1, 2008;
33(6):
1112 - 1116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. I. Khushalani
Cancer of the Esophagus and Stomach
Mayo Clin. Proc.,
June 1, 2008;
83(6):
712 - 722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Fletcher, B. Djulbegovic, H. P. Soares, B. A. Siegel, V. J. Lowe, G. H. Lyman, R. E. Coleman, R. Wahl, J. C. Paschold, N. Avril, et al.
Recommendations on the Use of 18F-FDG PET in Oncology
J. Nucl. Med.,
March 1, 2008;
49(3):
480 - 508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus
PET/CT of Esophageal Cancer: Its Role in Clinical Management
RadioGraphics,
November 1, 2007;
27(6):
1635 - 1652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Little, T. W. Rice, B. Bybel, D. P. Mason, S. C. Murthy, G. W. Falk, L. A. Rybicki, and E. H. Blackstone
Is FDG-PET indicated for superficial esophageal cancer?
Eur. J. Cardiothorac. Surg.,
May 1, 2007;
31(5):
791 - 796.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Ilson
Surgery After Primary Chemoradiotherapy in Squamous Cancer of the Esophagus: Is the Photon Mightier Than the Sword?
J. Clin. Oncol.,
April 1, 2007;
25(10):
1155 - 1156.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. F. Meyers, R. J. Downey, P. A. Decker, R. J. Keenan, B. A. Siegel, R. J. Cerfolio, R. J. Landreneau, C. E. Reed, D. M. Balfe, F. Dehdashti, et al.
The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial
J. Thorac. Cardiovasc. Surg.,
March 1, 2007;
133(3):
738 - 745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Gregoire, K. Haustermans, X. Geets, S. Roels, and M. Lonneux
PET-Based Treatment Planning in Radiotherapy: A New Standard?
J. Nucl. Med.,
January 1, 2007;
48(1_suppl):
68S - 77S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rizk, R. J. Downey, T. Akhurst, M. Gonen, M. S. Bains, S. Larson, and V. Rusch
Preoperative 18[F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values Predict Survival After Esophageal Adenocarcinoma Resection
Ann. Thorac. Surg.,
March 1, 2006;
81(3):
1076 - 1081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. van Westreenen, M. Westerterp, P. L. Jager, H. M. van Dullemen, G. W. Sloof, E. F.I. Comans, J. J. B. van Lanschot, T. Wiggers, and J. Th.M. Plukker
Synchronous Primary Neoplasms Detected on 18F-FDG PET in Staging of Patients with Esophageal Cancer
J. Nucl. Med.,
August 1, 2005;
46(8):
1321 - 1325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|